Is there a risk of rapid deterioration of the condition once furmonertinib is discontinued?

Furmonertinib (Furmonertinib) is a drug for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) The third-generation tyrosine kinase inhibitor (TKI) is mainly used for patients who develop T790M mutation after previous EGFR TKI treatment or who are intolerant to other EGFR inhibitors. Its mechanism of action is to block tumor cell proliferation and survival by selectively inhibiting the mutant EGFR signaling pathway. Since the drug is a targeted maintenance therapy and its efficacy relies on continued inhibition of EGFR signaling, discontinuation of the drug may have a direct impact on the condition.

Clinical studies and real-world data indicate that some patients may experience rapid tumor progression or worsening of disease after discontinuation of fumetinib. This phenomenon is called "drug withdrawal rebound". The main reason is that tumor cells regain EGFR signaling activity and quickly resume their proliferation ability. The speed of response to drug withdrawal varies among individual patients, including factors such as tumor burden, mutation type, and previous treatment history, but in most cases, signs of disease recurrence or progression may be observed within weeks to months after drug withdrawal.

Therefore, in clinical practice, discontinuation of fumetinib must be strictly followed Doctor's instructions must be strictly followed, and the drug must not be discontinued at will. For patients who experience serious adverse reactions or comorbidities, the risks and benefits should be weighed under the evaluation of a professional physician. If necessary, dose adjustment, short-term drug discontinuation, or replacement of other treatment options should be adopted instead of complete drug discontinuation. For patients whose condition may worsen rapidly after stopping the drug, doctors usually make follow-up treatment plans in advance, such as replacing other EGFR inhibitors or combining chemotherapy to avoid out-of-control tumors.

In general, there is a certain risk of rapid deterioration of the condition when discontinuing fumetinib, especially for patients whose condition is relatively stable but relies on drug control. Patients should maintain regular medication during medication, closely monitor symptoms and imaging changes, and promptly communicate with oncologists when encountering drug side effects or need for treatment adjustments to ensure that the condition is continuously controlled within a safe range.

Reference materials:https://www.drugs.com/